Victory Capital Management Inc. Sells 42,580 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Victory Capital Management Inc. trimmed its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 18.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 193,664 shares of the company's stock after selling 42,580 shares during the quarter. Victory Capital Management Inc. owned about 0.56% of Disc Medicine worth $9,613,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. FMR LLC boosted its position in Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company's stock valued at $118,320,000 after buying an additional 1,459,434 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Disc Medicine by 23.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company's stock valued at $88,421,000 after purchasing an additional 262,690 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Disc Medicine by 62.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company's stock valued at $77,170,000 after purchasing an additional 467,988 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Disc Medicine by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 1,068,246 shares of the company's stock valued at $67,727,000 after acquiring an additional 18,716 shares during the last quarter. Finally, Woodline Partners LP increased its position in shares of Disc Medicine by 5.2% in the fourth quarter. Woodline Partners LP now owns 396,600 shares of the company's stock valued at $25,144,000 after acquiring an additional 19,538 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

Insider Buying and Selling at Disc Medicine

In related news, Director Kevin Bitterman sold 29,837 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $60.97, for a total value of $1,819,161.89. Following the transaction, the director owned 647,002 shares of the company's stock, valued at approximately $39,447,711.94. This trade represents a 4.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John D. Quisel sold 34,800 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $55.33, for a total transaction of $1,925,484.00. Following the completion of the transaction, the chief executive officer directly owned 161,828 shares in the company, valued at approximately $8,953,943.24. The trade was a 17.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,338 shares of company stock worth $5,797,556 in the last quarter. 4.24% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on IRON. Truist Financial began coverage on Disc Medicine in a research report on Monday, July 21st. They set a "buy" rating and a $86.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $118.00 price target on shares of Disc Medicine in a research report on Thursday, July 3rd. Morgan Stanley began coverage on Disc Medicine in a research note on Thursday, July 3rd. They set an "overweight" rating and a $85.00 target price for the company. Wedbush restated an "outperform" rating and set a $90.00 target price on shares of Disc Medicine in a research note on Monday, July 21st. Finally, BMO Capital Markets increased their price target on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $95.73.

Disc Medicine Trading Down 1.9%

Disc Medicine stock traded down $1.13 during trading hours on Monday, reaching $59.48. 298,411 shares of the company's stock were exchanged, compared to its average volume of 336,763. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. The firm's 50 day simple moving average is $52.88 and its 200 day simple moving average is $51.34. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $68.73. The firm has a market capitalization of $2.06 billion, a PE ratio of -15.17 and a beta of 0.76.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Research analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.